EBI-031 is under clinical development by Sesen Bio and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect EBI-031’s likelihood of approval (LoA) and phase transition for Diabetic Macular Edema took place on 10 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their EBI-031 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
RG-6179 (EBI-031) is under development for the treatment of diabetic macular edema (DME) and uveitis. The drug candidate is administered through intravitreal route. It is a humanized monoclonal antibody targeting interleukin-6. It is developed based on AMP-Rx protein engineering technology.
Sesen Bio overview
Sesen Bio (Sesen) is a late-stage clinical company that develops targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. The company’s TFPTs genetically combines targeting antibody fragments with cytotoxic protein payloads. Sesen’s product pipeline includes Vicinium (VB4-845) also known as oportuzumab monatox, which is used for the treatment of high-grade non-muscle invasive bladder cancer; and also, for the treatment of late-stage squamous cell carcinoma of the head and neck (SCHN). The company operates in the US, the UK, and Canada. Sesen is headquartered in Cambridge, Massachusetts, the US.
Quick View EBI-031 LOA Data
|Highest Development Stage|